Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study

Annals of Surgical Oncology

Volumn 23, Issue 3, 2016, Pages 994-1002

  Hsu, Chia Yang ^a,b,c   Liu, Po Hong ^a,c   Hsia, Cheng Yuan ^a,c   Lee, Yun Hsuan ^a,c   Nagaria, Teddy S ^d   Lee, Rheun Chuan ^a,c   Lin, Han Chieh ^a,c   Huo, Teh Ia ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CALIBRATION; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILAN CRITERIA; MULTIPLE CANCER; NOMOGRAM; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURGICAL PATIENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR INVASION; TUMOR VOLUME; VALIDATION STUDY; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; FOLLOW UP; LIVER NEOPLASMS; LIVER RESECTION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROPENSITY SCORE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NOMOGRAMS; PROGNOSIS; PROPENSITY SCORE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84957851751     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4929-x     Document Type: Article

References (29)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.
2. Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, König J, Hoppe-Lotichius M et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol. 2014;48:279–89
3. Lopez PM, Villanueva A, Llovet JM. Systemic review: evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535–47.
4. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;31:461–76.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.
6. Liu PH, Lee YH, Hsia CY, Hsu CY, Huang YH, Chiou YY et al. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014;21:1825–33
7. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–9
8. Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol. 2010;17:2073–80.
9. Truty MJ, Vauthey JN. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol. 2010;17:1219–25.
10. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Pai JT et al. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol. 2012;19:842–9
11. Shim JH, Jun MJ, Han S, Lee YJ, Lee SG, Kim KM, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261:939–46
12. Massarweh NN, Dickson PV, Anaya DA. Soft tissue sarcomas: staging principles and prognostic nomograms. J Surg Oncol. 2015;111:532–9.
13. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30
14. Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Chiou YY et al. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int. 2013;7:645–54
15. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53:108–17.
16. Lee YH, Hsu CY, Huang YH, Hsia CY, Chiou YY, Su CW et al. Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. J Clin Gastroenterol. 2014;48:734–41.
17. Hsu CY, Lee YH, Liu PH, Hsia CY, Huang YH, Lin HC, et al. Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? PLoS One. 2015;10:e0118825.
18. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–87.
19. Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109–23.
20. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma: survival analysis of 3892 patients. Eur J Cancer. 2008;44:1000–6.
21. Yamashita Y, Taketomi A, Shirabe K, Aishima S, Tsuijita E, Morita K et al. Outcomes of hepatic resection for huge hepatocellular carcinoma (≥10 cm in diameter). J Surg Oncol. 2011;104:292–8.
22. Liu PH, Lee YH, Hsu CY, Hsia CY, Huang YH, Chiou YY, et al. Surgical resection is better than transarterial chemoembolization for hepatocellular carcinoma beyond Milan criteria independent of performance status. J Gastrointest Surg. 2014;18:1623–31
23. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70.
24. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57:112–9.
25. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol. 2013;20:2035–42
26. Mazzaferro V, Lencioni R, Majno P. Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. Semin Liver Dis. 2014;34:415–26.
27. Huo TI, Huang YH, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and look into future. J Chin Med Assoc. 2005;68:155–9.
28. Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35(Suppl 1):129–38.
29. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001.